May 2nd, 2011
FDA Approves New Drug for Type 2 Diabetes
Larry Husten, PHD
The FDA announced today that it has approved linagliptin, a new drug for type 2 diabetes. The DPP-4 inhibitor was developed by Eli Lilly and Boehringer Ingelheim and will be sold under the brand name of Tradjenta.
Linagliptin was studied in 3,800 patients with type 2 diabetes, the FDA said, and was better than placebo in controlling glucose. The drug has been studied as monotherapy and in combination with other drugs indicated for type 2 diabetes, but its use with insulin has not been tested and it should not be used in people with type 1 diabetes.
According to the FDA, the most common side effects of the drug are upper respiratory infection, stuffy or runny nose, sore throat, muscle pain, and headache.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?